Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations

AIDS

Volumn 19, Issue 7, 2005, Pages 731-733

  Johnston, Elizabeth ^a   Dupnik, Kathryn M ^a   Gonzales, Matthew J ^a   Winters, Mark A ^a   Rhee, Soo Yon ^a   Imamichi, Tomozumi ^a   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG RESEARCH; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS RESISTANCE;

EID: 17844409371     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000166098.54564.0c     Document Type: Article

References (16)

1. Gonzales MJ, Johnson E, Dupnik KM, Imamichi T, Shafer RW. Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing. J Acquir Immune Defic Syndr 2003; 34:398-402.
2. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
3. Rhee SY, Liu T, Ravela J, Gonzales MJ, Shafer RW. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother 2004; 48:3122-3126.
4. Gonzales MJ, Belitskaya I, Dupnik KM, Rhee SY, Shafer RW. Protease and reverse transcriptase mutation patterns in HIV type 1 isolates from heavily treated persons: comparison of isolates from Northern California with isolates from other regions. AIDS Res Hum Retroviruses 2003; 19:909-915.
5. Gallant J, Rodriguez AE, Weinberg W. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2003 [Abstract 1722a].
6. Landman R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalisherif A, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamiduvine, and tenofovir: the Tonus Study. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2004 [Abstract 52].
7. Roge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 2003; 8:173-182.
8. Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, Lane HC. Relative replication fitness of a high-level 3′-azido-3′- deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr(Gly) at codon 69. J Virol 2000; 74:10958-10964.
9. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type HIV-1. Antimicrob Agents Chemother 2004; 48: 437-443.
10. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.
11. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-846.
12. Molina JM, Marcelin AG, Pavie J, Merle C, Troccaz M, Leleu G, Calvez V. Didanosine (ddl) in treatment experienced HIV-infected patients: results from a randomized double-blind study (AI454-176 Jaguar). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2003. [Abstract H-447].
13. Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, et al. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. J Acquir Immune Defic Syndr 2002; 31:121-127.
14. Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 2003; 8:489-506.
15. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002; 15:247-277.
16. Faruki H, Sebastian J, Scott J, Stamp J, Lanier E. Changes in prevalence of NRTI resistance associated mutations among clinical isolates from 1999-2003. Antivir Ther 2004; 9:S91.